Under construction – not a live service
Sign in
Taking people in EgyptPhase 2

Tests metformin added to mesalamine for ulcerative colitis

Tests metformin alongside mesalamine in adults with ulcerative colitis.

Plain-language title generated from the registry record
Registry title: Metformin as Added on Therapy in Patients With Ulcerative Colitis

Key facts

Where
Al Mansurah, EgyptSee the site
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild or moderate ulcerative colitis confirmed by endoscopy. Metformin is added to mesalamine treatment.

Age
18 to 75 years
Sex
Men and women
Disease stage
Mild or moderate ulcerative colitis, diagnosed and confirmed by endoscope
Earlier treatment
People taking rectal or systemic steroids cannot join.

Main reasons for not taking part

  • Breastfeeding
  • Significant liver or kidney function problems
  • Diabetes
  • Colorectal cancer
  • Severe ulcerative colitis

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT05574387, who can take part

Where in Egypt

  • Faculty of Medicine, Mansoura UniversityAl Mansurah, EgyptContact: Mostafa Bahaa, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Tanta University
Trial code
NCT05574387
Record updated
4 March 2025
Original description
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilizationRead full original descriptionShow less

Metformin, The Biguanide Derivative, as Adjuvant Therapy in Patients With Ulcerative Colitis Treated With Mesalamine

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilization

Inclusion: Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception Mild and moderate UC patients diagnosed and confirmed by the endoscope.

Exclusion: Breastfeeding Significant liver and kidney function abnormalities Diabetic patients Colorectal cancer patients Patients with severe UC Patients taking rectal or systemic steroids.

ClinicalTrials.gov NCT05574387